Impact of seal oil on rheumatoid arthritis symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of DPA-rich seal oil in alleviating symptoms associated with rheumatoid arthritis. It is a multi-center, randomized, double-blind study involving 130 participants diagnosed with rheumatoid arthritis. The study will assess various outcomes, including disease activity, quality of life, and inflammatory biomarkers, using established clinical measures and questionnaires. Participants will be randomly assigned to receive either the seal oil treatment or a control, allowing for a robust comparison of results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have been diagnosed with RA after the age of 18;
* Have had RA for at least 1 year;
* Meet the 2010 ACR/EULAR criteria;
* Stable disease status for at least 3 months:

  * Low to moderate activity as measured by the Clinical Disease Activity Index (CDAI);
  * Stable dose of DMARD (conventional synthetic Disease Modifying Anti-Rheumatic Drug) for at least 3 months;
  * Stable dose of NSAIDs and corticosteroids for at least 1 month;
  * Do not take \> 10 mg per day of prednisone.

Exclusion Criteria:

* Have been diagnosed with another rheumatologic autoimmune disease;
* Have been diagnosed with inflammatory bowel disease (ulcerative colitis or Crohn's disease);
* Have a disease that may interfere with the physician's assessment (e.g. severe osteoarthritis);
* Have fibromyalgia;
* Consume omega-3 fatty acid supplements other than those given during the project;
* Have an allergy or intolerance to seafood;
* Consume natural health products that may potentially affect inflammation (e.g. glucosamine, chondroitin, devil's claw, curcumin products) during the project;
* Consume more than two servings (1 serving = 90 g or 3 ounces) of fish and seafood per week for the duration of the study;
* Take anticoagulant medication;
* Be treated or have previously received biological agents or inhibitors of JAK (Janus kinase) (family of tyrosine kinases).

Where it's running

• Grmo
  Québec, Canada Recruiting

Study contacts

• Principal investigator: Alain Doyen, PhD — Laval University
• Study coordinator: Louise Corneau, MSc
• Email: louise.corneau@fsaa.ulaval.ca
• Phone: 418-656-2131

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collection of biological samples for diagnosing rare neurological diseases

  This study is collecting blood and spinal fluid samples from people with rare neurological diseases to see if they can find new markers that help diagnose these conditions more accurately.

  Recruiting Hospices Civils de Lyon · Bron · NCT05370079

• Validation of a French version of a compliance questionnaire for rheumatology

  This study is testing a French version of a questionnaire to see how well it helps patients with rheumatoid arthritis understand and follow their methotrexate treatment.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Bordeaux and 3 other locations · NCT03642795

• Post-marketing surveillance of a femoral stem prosthesis for hip replacement

  This study is tracking how well a specific hip replacement device works and its safety in people aged 18 to 75 who are having hip surgery for different joint problems.

  Recruiting at 4 sites Medacta International SA · Vienna and 3 other locations · NCT02748408

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.